Lilly Submits New Amyvid Data For Medicare National Coverage Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Physicians in study changed their diagnosis of whether a patient had Alzheimer’s in half of cases after receiving data from PET scans using Lilly’s beta amyloid detecting tracer Amyvid. Study findings were not available when Lilly first asked CMS to conduct the coverage analysis.